ADAM17 and non-small cell lung carcinoma: This study explored and preliminarily clarified that ADAM10 may play a major role in NSCLC compared with ADAM17, and miR-140-3p is not only one of the possible mechanisms of ADAM10 overexpression in NSCLC, but also can potentially be used as a new therapeutic strategy targeting ADAM10.